Big Data portal for Alzheimers drug discovery launched
The National Institutes of Health (NIH) and
its partners have launched a new Big Data portal, the AMP-AD
Knowledge Portal, to speed Alzheimer’s drug discovery.
“We are determined to reduce the cost and
time it takes to discover viable therapeutic targets and bring new diagnostics
and effective therapies to people with Alzheimer’s. That demands a new way of
doing business,” said NIH Director Francis S. Collins, M.D., Ph.D.
The AMP-AD Knowledge Portal enables the wider
research community to share and analyze large and complex biomedical datasets.
The goal is for researchers to ramp up the development of predictive models of
Alzheimer’s disease and find novel targets that drive the clinical signs and
symptoms of the disease.
The new data sharing and analysis resource is
part of the Accelerating Medicines Partnership-Alzheimer’s
Disease (AMP-AD) initiative, a partnership among government, industry, and
nonprofit organizations including NIH, the U.S. Food and Drug Administration,
industry and academic scientists from a variety of disciplines. The Portal was
developed by Sage Bionetworks, a Seattle-based non-profit organization promoting
Share this information on social media with
the following message: